Document is current
Any future updates will be listed below
-
Authors
Kim, Daehwan
Chung, Heekyung
Liu, Wen
Jeong, Kangjin
Ozmen, Tugba Y.
Ozmen, Furkan https://orcid.org/0000-0002-1128-9458
Rames, Matthew J. https://orcid.org/0000-0001-9968-1624
Kim, Sangyub
Guo, Xiao
Jameson, Nathan
de Jong, Petrus R.
Yea, Steven
Harford, Laurie
Li, Jiali
Mathews, Cara A.
Doroshow, Deborah B.
Charles, Vincent J.
Kim, Doris
Fischer, Kimberlee
Samatar, Ahmed A.
Jubb, Adrian
Bunker, Kevin D.
Blackwell, Kimberly
Simpkins, Fiona
Meric-Bernstam, Funda https://orcid.org/0000-0001-6816-6072
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Harismendy, Olivier
Ma, Jianhui https://orcid.org/0000-0002-9374-2673
Lackner, Mark R.
- License Information
-
More Information
Article History
Received: 9 May 2024
Accepted: 13 December 2024
First Online: 4 January 2025
Competing interests
: D. Kim is an employee and shareholder of Zentalis Pharmaceuticals. H. Chung is an employee and shareholder of Zentalis Pharmaceuticals. W. Liu is an employee and shareholder of Zentalis Pharmaceuticals. S. Kim is an employee and shareholder of Zentalis Pharmaceuticals. X. Guo is an employee and shareholder of Zentalis Pharmaceuticals. N. Jameson is an employee and shareholder of Zentalis Pharmaceuticals. P.R. de Jong is a former employee of Zentalis Pharmaceuticals. S. Yea is a former employee and shareholder of Zentalis Pharmaceuticals. L. Harford is a former employee and shareholder of Zentalis Pharmaceuticals. J. Li is a former employee of Zentalis Pharmaceuticals. D. Kim is an employee and shareholder of Zentalis Pharmaceuticals. K. Fischer is an employee and shareholder of Zentalis Pharmaceuticals. A. Samatar is a former employee of Zentalis Pharmaceuticals and shareholder in Zentalis Pharmaceuticals. A. Jubb is a former employee and shareholder of Zentalis Pharmaceuticals. K. Bunker is a former employee of Zentalis Pharmaceuticals and shareholder in Zentalis Pharmaceuticals. K. Blackwell is a former employee and shareholder of Zentalis Pharmaceuticals. F. Simpkins serves on scientific advisory boards for AstraZeneca, GSK and Zentalis Pharmaceuticals; has received institutional research funding from AstraZeneca, Repare Therapeutics, Instill Bio and Sierra Oncology. F. Meric-Bernstam is consultant for. AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd., Calibr (a division of Scripps Research), DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, Exelixis, F. Hoffman-La Roche Ltd., GT Apeiron, Genentech Inc., Harbinger Health, IBM Watson, Incyte, Infinity Pharmaceuticals, Jackson Laboratory, Jazz Pharmaceuticals, Kolon Life Science, LegoChem Bio, Lengo Therapeutics, Loxo Oncology, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd, Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks; Advisory Committee for Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals, Theratechnologies, Zentalis; Received sponsored Research (to the institution) from Jazz Pharmaceuticals, Zymeworks, Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co.; Honoraria for Dava Oncology; receiving travel related funding and reimbursement from European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), Cholangiocarcinoma Foundation, Dava Oncology. G.B. Mills is scientific advisory board/Consultant for Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, GSK, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals; Stock/Options/Financial: Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, Turbine; Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring; Sponsored research: AstraZeneca. O. Harismendy is an employee and shareholder of Zentalis Pharmaceuticals. J. Ma is an employee and shareholder of Zentalis Pharmaceuticals. M.R. Lackner is an employee and shareholder of Zentalis Pharmaceuticals. No disclosures were reported by the other authors.
